Pyxis Oncology, Inc. — Director's Dealing 2021

Oct 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-10-13

Reporting Person: Bayer World Investments B.V. (Former 10% Owner)
Reporting Person: BAYER AKTIENGESELLSCHAFT (Former 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-13	Common Stock	C	2742338	—	Acquired	2742338	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-13	Series A Convertible Preferred Stock	$	C	11362462	Disposed		Common Stock (1786831)	Direct
2021-10-13	Series B Convertible Preferred Stock	$	C	6076072	Disposed		Common Stock (955507)	Direct

Footnotes

F1: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.